Gene therapy is currently one of the most exciting areas of pharmaceuticals development. Leading researchers and scientists over the world are committed to fulfilling the promise that gene therapy can radically improve the quality of life for millions of people. This dynamic research and development environment is home to CombiGene, Sweden’s only listed gene therapy company.
CombiGene’s management group, with CEO Jan Nilsson, Chief Research and Development Officer Karin Agerman and board chairman Arne Ferstad, participate regularly in international congresses and other events to build long-term contacts with other companies in the industry and present CombiGene’s plans and development for investors.
This autumn CombiGene will take part in the following events:
22-24 October 2018
Conference: 2nd Annual Gene therapy for Rare Disorders Europe
Venue: Novotel London West, London, UK
CombiGene’s CEO Jan Nilsson, Chief Research and Development Officer Karin Agerman and board chairman Arne Ferstad will attend. Jan Nilsson will also take part in the panel discussion “The Next Step – Pioneering Gene Therapies in More Common Diseases”, 24 October at 11.30 a.m.
Read more: http://genetherapy-europe.com/
5-6 November 2018
Conference: BIO Europe
Venue: Bella Center Copenhagen, Copenhagen, Denmark
BIO Europe, Europe’s biggest life science partnering conference, is an important forum where CombiGene can meet potential partners in a range of disciplines. CombiGene will be represented by the company’s Chief Research and Development Officer Karin Agerman, who will take part in a panel discussion entitled “Partnering landscape in advanced therapies”, on 6 November at 11.00 a.m.
Read more: https://ebdgroup.knect365.com/bioeurope/
20 November 2018
Presentation: Gene therapy: the future treatment for epilepsy?
Venue: Epilepsy Association in Greater Stockholm. Merab Kokaia, Professor of Neurophysiology and head of the Epilepsy Centre, Lund University Faculty of Medicine, discusses the challenges and opportunities implicit in turning an idea into an approved drug.